Torrent Pharma gets certain USFDA observations for Indrad plant

The audit at Indrad plant of Torrent Pharma was carried out by the United States Food and Drug Administration (USFDA) in April.

New Delhi: Drug firm Torrent Pharmaceuticals Friday said the US health regulator has made 'certain' observations after inspection of its Indrad facility in Gujarat. The audit at Indrad plant of the company was carried out by the United States Food and Drug Administration (USFDA) in April.

"We have received certain observations which are procedural in nature and the company is confident of addressing them satisfactorily," Torrent Pharmaceuticals said in a BSE filing.

Also Read: Refix Ceiling Price of Torrent pharmas Trilosar 6.25, 12.5 : DoP directs NPPA

The company, however, did not quantify how many observations were made by the US health regulator.

As per the USFDA, an "FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts".

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group. Based in the Indian city of Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gyneacology and pediatric segments.

Also Read: Torrent Pharma recalls over 10.78 lakh bottles of Losartan citing CGMP deviations